AMBEA Stock Analysis: Ambea | ST
Medical Care Facilities | ST, Sweden | Market Cap: 13.982m SEK | 12M Return: 33.1% | SE0009663826 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.6M
EPS Trend: 93.6%
Qual. Beats: 1
Rev. Trend: 98.1%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 9.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ambea AB is a Nordic health care services provider operating in Sweden, Norway, and Denmark. The company delivers elderly care, disability care, and psychosocial support services through multiple branded segments, including Vardaga (nursing homes and home care for the elderly), Nytida (social care and schools for children with neuropsychiatric disorders), Stendi (personal assistance and social care), Altiden (disability and home care), Klara (staff solutions for social welfare services), Lära (training and coaching), and Validia (residential and rehabilitation services).
The company is headquartered in Solna, Sweden, was incorporated in 1993, and originally operated under the name H-Careholding AB before adopting its current name in September 2007. As a participant in the Health Care Facilities sub-industry, Ambea operates in a regulated sector where care services are typically procured or funded through public welfare systems in the Nordic region.
- Sweden elderly care pricing renegotiation pressures Vardaga margins
- Rising staff costs across Nordic operations squeeze profitability
- M&A pipeline and demographic tailwinds support long-term segment growth
| Net Income: 788.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.16 > 1.0 |
| NWC/Revenue: -17.18% < 20% (prev -15.35%; Δ -1.82% < -1%) |
| CFO/TA 0.11 > 3% & CFO 2.33b > Net Income 788.0m |
| Net Debt (22.7b) to EBITDA (2.98b): 7.60 < 3 |
| Current Ratio: 0.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.3m) vs 12m ago -4.68% < -2% |
| Gross Margin: 30.86% > 18% (prev 78.49%; Δ -47.63% > 0.5%) |
| Asset Turnover: 79.82% > 50% (prev 69.95%; Δ 9.88% > 0%) |
| Interest Coverage Ratio: 2.60 > 6 (EBIT TTM 1.48b / Interest Expense TTM 569.0m) |
| A: -0.14 (Total Current Assets 2.00b - Total Current Liabilities 4.90b) / Total Assets 21.0b |
| B: -0.05 (Retained Earnings -1.07b / Total Assets 21.0b) |
| C: 0.07 (EBIT TTM 1.48b / Avg Total Assets 21.2b) |
| D: 0.32 (Book Value of Equity 5.14b / Total Liabilities 15.9b) |
| Altman-Z'' = -0.26 = B |
| DSRI: 0.73 (Receivables 1.72b/2.06b, Revenue 16.9b/14.9b) |
| GMI: 2.54 (GM 78.49% / 30.86%) |
| AQI: 1.03 (AQ_t 0.45 / AQ_t-1 0.43) |
| SGI: 1.13 (Revenue 16.9b / 14.9b) |
| TATA: -0.07 (NI 788.0m - CFO 2.33b) / TA 21.0b) |
| Beneish M = -1.74 (Cap -4..+1) = CCC |
As of September 27, 2026, the stock is trading at SEK 173.10 with a total of 131,699 shares traded. Over the past week, the price has changed by -0.57%, over one month by -0.29%, over three months by +25.07% and over the past year by +33.14%.
Current recommended Stop Loss: 167.30 (which is 3.4% or 1.2 ATR below the current price).
Ambea has no consensus analysts rating.
P/E Trailing = 18.2878
P/S = 0.8238
P/B = 2.7202
Revenue TTM = 16.9b SEK
EBIT TTM = 1.48b SEK
EBITDA TTM = 2.98b SEK
Long Term Debt = 2.25b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.56b SEK (from shortTermDebt, last quarter)
Debt = 22.7b SEK (from shortLongTermDebtTotal, last quarter) + Leases 9.52b
Net Debt = 22.7b SEK (calculated: Debt 22.7b - CCE 62.0m)
Enterprise Value = 36.7b SEK (14.0b + Debt 22.7b - CCE 62.0m)
Interest Coverage Ratio = 2.60 (Ebit TTM 1.48b / Interest Expense TTM 569.0m)
EV/FCF = 16.63x (Enterprise Value 36.7b / FCF TTM 2.20b)
FCF Yield = 6.01% (FCF TTM 2.20b / Enterprise Value 36.7b)
FCF Margin = 13.03% (FCF TTM 2.20b / Revenue TTM 16.9b)
Net Margin = 4.66% (Net Income TTM 788.0m / Revenue TTM 16.9b)
Gross Margin = 30.86% ((Revenue TTM 16.9b - Cost of Revenue TTM 11.7b) / Revenue TTM)
Gross Margin QoQ = 7.70% (prev 7.77%)
Tobins Q-Ratio = 1.74 (Enterprise Value 36.7b / Total Assets 21.0b)
Interest Expense / Debt = 2.50% (Interest Expense 569.0m / Debt 22.7b)
Taxrate = 21.36% (214.0m / 1.00b)
NOPAT = 1.16b (EBIT 1.48b * (1 - 21.36%))
Current Ratio = 0.41 (Total Current Assets 2.00b / Total Current Liabilities 4.90b)
Debt / Equity = 4.42 (Debt 22.7b / totalStockholderEquity, last quarter 5.14b)
Debt / EBITDA = 7.60 (Net Debt 22.7b / EBITDA 2.98b)
Debt / FCF = 10.29 (Net Debt 22.7b / FCF TTM 2.20b)
Total Stockholder Equity = 5.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.72% (Net Income 788.0m / Total Assets 21.0b)
RoE = 15.11% (Net Income TTM 788.0m / Total Stockholder Equity 5.22b)
RoCE = 19.80% (EBIT 1.48b / Capital Employed (Equity 5.22b + L.T.Debt 2.25b))
RoIC = 6.24% (NOPAT 1.16b / Invested Capital 18.6b)
WACC = 3.63% (E(14.0b)/V(36.7b) * Re(6.34%) + D(22.7b)/V(36.7b) * Rd(2.50%) * (1-Tc(0.21)))
Discount Rate = 6.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.60 | Cagr: -4.43%
[DCF] Terminal Value 77.97% ; FCFF base≈2.03b ; Y1≈2.33b ; Y5≈3.43b
[DCF] Fair Price = 360.1 (EV 51.6b - Net Debt 22.7b = Equity 28.9b / Shares 80.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 93.62 | EPS CAGR: 30.15% | SUE: 1.40 | # QB: 1
Revenue Correlation: 98.14 | Revenue CAGR: 9.91% | SUE: 2.05 | # QB: 3
EPS current Quarter (2026-09-30): EPS=4.33 | Chg30d=-0.23% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=10.86 | Chg30d=+5.03% | Revisions=+40% | GrowthEPS=+37.1% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=12.45 | Chg30d=+5.42% | Revisions=+40% | GrowthEPS=+14.6% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: +44% (up=5, down=1)